Version May 2024
Note: Dritho-Creme HP has been discontinued in the United States for >1 year.
Psoriasis: Topical:
Cream: Generally, apply once daily or as directed. The irritant potential of anthralin is directly related to the strength being used and each patient's individual tolerance. Always commence treatment using a short, daily contact time (5 to 10 minutes) for at least 1 week using the lowest strength possible. Contact time may be gradually increased (to 30 minutes) as tolerated.
Skin application: Apply sparingly only to psoriatic lesions and rub gently and carefully into the skin until absorbed. Avoid applying an excessive quantity which may cause unnecessary soiling and staining of the clothing or bed linen.
Scalp application: Comb hair to remove scalar debris, wet hair and, after suitably parting, rub cream well into the lesions, taking care to prevent the cream from spreading onto the forehead.
Note: Remove by washing or showering; optimal period of contact will vary according to the strength used and the patient's response to treatment. Continue treatment until the skin is entirely clear (ie, when there is nothing to feel with the fingers and the texture is normal).
Shampoo: Rub shampoo onto wet scalp, lather and leave on scalp for 3 to 5 minutes; rinse thoroughly; apply 3 to 4 times weekly
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
(For additional information see "Anthralin: Pediatric drug information")
Note: Dritho-Creme HP has been discontinued in the United States for >1 year.
Scalp psoriasis: Children ≥12 years and Adolescents: Topical: Shampoo: Rub shampoo onto wet scalp, lather and leave on scalp for 3 to 5 minutes; rinse thoroughly; apply 3 to 4 times weekly.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Dermatologic: Allergic contact sensitivity, erythema, hair discoloration (temporary), nail discoloration (temporary), skin discoloration (temporary)
Miscellaneous: Transient irritation (uninvolved skin)
Hypersensitivity to anthralin or any component of the formulation; acute psoriasis (acutely or actively inflamed psoriatic eruptions)
Concerns related to adverse effects:
• Redness: If redness is observed, reduce frequency of dosage or discontinue application.
• Staining: May stain skin, hair, fingernails (temporary), or fabrics (may be permanent).
Other warnings/precautions:
• Appropriate application: Avoid eye contact; should generally not be applied to opposing skin surfaces that may rub or touch (eg, skin folds of the groin, axilla, and breasts) and high strengths should not be used on these sites; do not apply to genitalia.
• Prolonged/extensive use: Use with caution in patients extensive and prolonged applications.
Dritho-Creme HP has been discontinued in the United States for >1 year.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Cream, External:
Dritho-Creme HP: 1% (50 g [DSC]) [contains methylparaben]
Shampoo, External:
Zithranol: 1% (85 g) [contains fd&c blue #1 (brilliant blue)]
No
Shampoo (Zithranol External)
1% (per gram): $13.55
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
May apply using latex gloves to prevent staining of fingers. Apply directly to plaques; rub in gently but thoroughly; avoid application to unaffected skin. When applying to scalp, part hair in one-inch segments to reach plaques. Remove by washing after conclusion of prescribed contact period. When rinsing, take care to avoid contact with eyes. Immediately clean tub or shower to prevent staining. Dry off using old towel (stains on fabric may be permanent). Petroleum jelly may be used around the edges of plaques, in body folds, or skin creases to prevent irritation of unaffected skin.
Topical: May apply using latex gloves to prevent staining of fingers
Cream: Adults: Apply directly to plaques; rub in gently but thoroughly; avoid application to unaffected skin. Petroleum jelly may be used around the edges of plaques, in body folds, or skin creases to prevent irritation of unaffected skin.
Shampoo: When applying to scalp, part hair in 1-inch segments to reach plaques. Remove by washing after conclusion of prescribed contact period. When rinsing, take care to avoid contact with eyes. Immediately clean tub or shower to prevent staining. Dry off using old towel (stains on fabric may be permanent).
Plaque psoriasis: Treatment of chronic plaque psoriasis
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Risk X: Avoid combination
Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Risk C: Monitor therapy
Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). Risk C: Monitor therapy
Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Risk C: Monitor therapy
Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy
Animal reproduction studies have not been conducted.
It is not known if anthralin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.
Reduction of the mitotic rate and proliferation of epidermal cells in psoriasis by inhibiting synthesis of nucleic protein from inhibition of DNA synthesis to affected areas
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
